We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urine Tests Could Reveal Early Signs of Cancer and Other Diseases

By LabMedica International staff writers
Posted on 24 Oct 2024

Early detection is essential for effectively treating diseases such as cancer, yet not everyone has convenient access to screening tools. More...

For issues affecting the genitourinary (GU) tract, which includes the kidneys, prostate, and bladder, healthcare providers typically employ a combination of screening methods, including blood tests, imaging, and physical examinations. Researchers are now developing an even simpler tool for early disease screening—urine analysis.

A new study by a team of scientists, including researchers from the University of Texas at Arlington (UTA; Arlington, TX, USA), has shown that analyzing RNA (a type of genetic material) and other substances present in urine can indicate changes in cell types, potentially revealing early signs of cancer and other diseases. This approach could assist clinicians in identifying issues earlier when they are more easily treatable without requiring invasive procedures. In the study, the researchers collected urine samples from two groups: healthy individuals and those with kidney stones. They extracted two types of RNA from the urine—cell-free RNA, which is suspended freely in the urine, and sediment RNA, derived from solid particles. The RNA types were sequenced and analyzed, comparing samples from healthy individuals with those from patients who had kidney stones.

The findings of the study were published in Clinical Chemistry, a journal of the Association for Diagnostics & Laboratory Medicine (ADLM), revealing that advanced urine analyses could identify cellular patterns that indicate the presence of disease. The next phase of the research focuses on employing advanced machine learning techniques to further refine the differences detectable when comparing the RNA and protein signatures of healthy individuals to those diagnosed with diseases. The researchers aim to identify additional biomarkers that could facilitate the development of simpler, less invasive diagnostic methods in the future.

“We’re excited about this new research as it may lead to new, easier screening tools that can help detect diseases of the bladder, kidneys, and prostate,” said Joseph Buonomo, assistant professor of chemistry at UTA and an author of the study. “Although our patient cohort was small, it lays the groundwork for development of a type of ‘non-invasive liquid biopsy’ that will be used to track the progression of ailments like kidney stones, diabetes, and cancer using urine instead of surgical specimens.” 

Related Links:
University of Texas at Arlington


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
HPV Test
Allplex HPV28 Detection
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.